Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab in chronic spontaneous urticaria
NCT03749135Phase 2Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Nov 2018
- Primary completion
- Jul 2021
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dupilumab in chronic spontaneous urticaria (CSU) and recurrent angioedema, sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: Urticaria Activity Score over 7 days at 16 weeks. Started Nov 2018; status: completed.
02
Drugs
03
Conditions
chronic spontaneous urticaria (CSU)recurrent angioedema
Beyond the preview
Go deeper on NCT03749135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03749135.